| Literature DB >> 30021610 |
Dima Chbeir1,2, Jean Gaschignard1,2, Ronan Bonnefoy2,3, Constance Beyler2,3, Isabelle Melki1,2, Albert Faye1,2, Ulrich Meinzer4,5,6.
Abstract
BACKGROUND: Kawasaki disease (KD) is an acute febrile systemic vasculitis that affects small and medium blood vessels. Intensified treatments for the most severely affected patients have been proposed recently, and the early identification of KD patients at high risk for coronary artery aneurysms (CAA) is crucial. However, the risk scoring systems developed in Japan have not been validated in European populations, and little data is available concerning the link between initial echocardiogram findings other than high z-scores and cardiac prognosis.Entities:
Keywords: Kawasaki disease; Pediatric Rheumatology; Vasculitis; coronary artery
Mesh:
Substances:
Year: 2018 PMID: 30021610 PMCID: PMC6052519 DOI: 10.1186/s12969-018-0264-7
Source DB: PubMed Journal: Pediatr Rheumatol Online J ISSN: 1546-0096 Impact factor: 3.054
Patients’ characteristics according to the response to immunoglobulin infusion (N = 157)
| Resistant ( | Responder ( |
| |
|---|---|---|---|
| Demographics | |||
| Sex (M/F) | 24/21 | 68/44 | .36 |
| Age | 31 [24–40] | 31 [27–36] | .96 |
| < 12 months | 13 (29) | 22 (20) | .39 |
| 12–23 months | 7 (16) | 34 (30) | .10 |
| ≥ 24 months | 25 (55) | 56 (50) | .47 |
| Clinics | |||
| Fever length before Ig (days) | 7 [5–8] | 7 [6–8] | .33 |
| Lymphadenopathy | 18 (40) | 47 (42) | .72 |
| Rash | 39 (87) | 91 (81) | .63 |
| Conjunctivitis | 39 (87) | 76 (68) |
|
| Enanthem | 33 (73) | 89 (79) | .67 |
| Modification of the extremities | 18 (40) | 51 (46) | .47 |
| Fever length after Ig (hours) | 60 [56–64] | 24 [21–36] |
|
| Biology | |||
| Neutrophils (%) | 70 [66–74] | 65 [62–69] | .17 |
| Platelet count (G/L) | 434,900 [375,140-494,680] | 392,000 [361,860-421,420] | .31 |
| Hemoglobin (g/dl) | 10.4 [9.6–10.4] | 10.7 [10.4–10.9] | .60 |
| CRP (mg/L) | 182 [159–207] | 145 [131–160] |
|
| ΔCRP (%) | 41 [30–52] | 61 [56–66] |
|
| ASAT (UI/L) | 46 [39–54] | 60 [44–74] | .32 |
| ALAT (UI/L) | 55 [42–69] | 76 [54–98] | .73 |
| Bilirubin (μmol/L) | 10 [6–14] | 12 [8–15] | .91 |
| LDH (UI/L) | 781 [611–950] | 1442 [1073-1810] | .62 |
| Albumin (g/L) | 23 [21–25] | 26 [25–27] | .16 |
| Sodium (mmol/L) | 135 [134–136] | 135 [134–136] | .44 |
| Scores | |||
| Kobayashi | 1 | ||
| < 5 | 32 (78) | 86 (78) | |
| ≥ 5 | 9 (22) | 25 (22) | |
| Egami | .49 | ||
| < 3 | 32 (76) | 88 (82) | |
| ≥ 3 | 10 (24) | 19 (18) | |
| Sano | .50 | ||
| < 2 | 22 (67) | 66 (73) | |
| ≥ 2 | 11 (33) | 24 (27) | |
| Treatments | |||
| 1st dose IV Ig | 45 (100) | 112 (100) | 1 |
| 2nd dose IV Ig | 20 (40) | 1 |
|
| Corticosteroids | 17 (39) | 2 (2) |
|
| First echocardiogram results | |||
| Normal | 23 (51) | 86 (77) |
|
| Abnormal | 22 (49) | 26 (23) |
|
| Coronary artery dilatation | 11 (24) | 13 (12) |
|
| Pericardial effusion | 7 (16) | 8 (7) | .13 |
| Perivascular brightness of the coronary arteries | 4 (9) | 3 (3) | .10 |
| CAA | 3 (7) | 4 (4) | .40 |
| Small (< 5 mm) | 1 (2) | 2 (2) | 1 |
| Median (5–8 mm) | 1 (2) | 2 (2) | 1 |
| Giant (> 8 mm) | 1 (2) | 0 | .28 |
| Left ventricular dysfunction | 4 (9) | 2 (2) |
|
| Mitral insufficiency | 1 (2) | 1 (1) | .48 |
| Abnormal late echocardiograms | |||
| 6 weeks | 10 (22) | 8 (7) |
|
| Coronary artery dilatation | 5 | 2 | |
| Pericardial effusion | 1 | 0 | |
| Perivascular brightness of the coronary arteries | 1 | 0 | |
| CAA | 3 | 6 | |
| Small (< 5 mm) | 0 | 4 | |
| Median (5–8 mm) | 2 | 2 | |
| Giant (> 8 mm) | 1 | 0 | |
| Long-term | 4 (9) | 3 (3) | .10 |
| Coronary artery dilatation | 2 | 0 | |
| CAA | 2 | 3 | |
| Small (< 5 mm) | 1 | 3 | |
| Median (5–8 mm) | 1 | 0 | |
| Giant (> 8 mm) | 0 | 0 | |
Sole p-values < 0.05 are in boldfaced and p-values = 0.05 are not in boldfaced
Characteristics of patients’ with initial echocardiogram prior to immunoglobulin infusion according to the response to immunoglobulin infusion (N=58)
| Resistant ( | Responder ( |
| |
|---|---|---|---|
| Demographics | |||
| Sex (M/F) | 9/7 | 24/18 | 1 |
| Age (mean) | 33 | 29 | 0.32 |
| < 12 months | 8 (50) | 11 (26) | 0.12 |
| 12–23 months | 1 (6) | 10 (24) | 0.26 |
| ≥ 24 months | 7 (44) | 21 (50) | 0.77 |
| Clinics | |||
| Fever length before Ig (days) | 6 [5–8] | 7 [6–8] | .35 |
| Lymphadenopathy | 7 (44) | 17 (40) | 1 |
| Rash | 11 (69) | 32 (76) | .74 |
| Conjunctivitis | 12 (75) | 25 (60) | .37 |
| Enanthem | 8 (50) | 30 (71) | .14 |
| Modification of the extremities | 5 (31) | 22 (52) | .24 |
| Fever length after Ig (hours) | 62 [58–64] | 24 [20–36] | < 10−10 |
| Biology | |||
| Platelets | 463,500 | 405,900 | .61 |
| Neutrophils (%) | 66 | 64 | .47 |
| Hemoglobin (g/dl) | 10.3 | 10.3 | .91 |
| CRP (mg/L) | 172 | 140 | .23 |
| ΔCRP (%) | 48 | 62 | .08 |
| ASAT (UI/L) | 46 | 61 | .31 |
| ALAT (UI/L) | 49 | 81 | .15 |
| Bilirubin (μmol/L) | 17 | 10 | .54 |
| LDH (UI/L) | 855 | 636 | .66 |
| Albumin (g/L) | 26 | 27 | .96 |
| Sodium (mmol/L) | 136 | 136 | .70 |
| Scores | |||
| Kobayashi | .66 | ||
| < 5 | 10 (91) | 29 (81) | |
| ≥ 5 | 1 (9) | 7 (19) | |
| Egami | 1 | ||
| < 3 | 9 (75) | 26 (72) | |
| ≥ 3 | 3 (25) | 10 (28) | |
| Sano | .69 | ||
| < 2 | 5 (63) | 23 (70) | |
| ≥ 2 | 3 (37) | 10 (30) | |
| Treatments | |||
| 1st dose IV Ig | 15 (100) | 43 (100) | 1 |
| 2nd dose IV Ig | 5 (33) | 0 (0) |
|
| Corticosteroids | 5 (33) | 1 (2) |
|
| First echocardiogram results | |||
| Normal | 4 (25) | 25 (60) |
|
| Abnormal | 12 (75) | 17 (40) |
|
| Coronary artery dilatation | 4 (25) | 5 (12) | .24 |
| Pericardial effusion | 3 (19) | 6 (14) | .70 |
| Perivascular brightness of the coronary arteries | 1 (7) | 2 (5) | .53 |
| CAA | 1 (7) | 2 (5) | .53 |
| Small (< 5 mm) | 0 | 1 | |
| Median (5–8 mm) | 0 | 1 | |
| Giant (> 8 mm) | 1 | 0 | |
| Left ventricular dysfunction | 1 | 2 | |
| Mitral insufficiency | 0 | 0 | |
| Abnormal late echocardiograms | |||
| 6 weeks | 8 (50) | 5 (12) |
|
| Coronary artery dilatation | 5 (31) | 1 (2) | .004 |
| Pericardial effusion | 1 (7) | 0 | .28 |
| Perivascular brightness of the coronary arteries | 0 | 0 | 1 |
| CAA | 2 (13) | 4 (9) | .66 |
| Small (< 5 mm) | 0 | 2 | |
| Median (5–8 mm) | 1 | 2 | |
| Giant (> 8 mm) | 1 | 0 | |
| Long-term | 3 (19) | 2 (5) | .12 |
| Coronary artery dilatation | 2 | 0 | |
| CAA | 1 | 2 | |
| Small (< 5 mm) | 1 | 2 | |
| Median (5–8 mm) | 0 | 0 | |
Sole p-values < 0.05 are in boldfaced and p-values = 0.05 are not in boldfaced